Xa因子抑制对外周动脉疾病患者凝血、血小板反应性及血栓形成的影响
前瞻性研究纳入141例外周动脉疾病下肢血运重建患者,围术期系列血栓弹力图-血小板映射分析共471份样本。直接口服抗凝药(DOAC)组较单抗血小板组R时间延长但血小板抑制更少;发生主要不良肢体事件(MALE)者更多使用DOAC且R时间延长、最大凝血块振幅(MA)增高。
要点
- DOAC联合单抗血小板较单抗血小板R时间延长,但血小板抑制更少。
- 双抗血小板治疗组血小板抑制程度高于DOAC联合单抗血小板组及单抗血小板组。
- 发生MALE者更多使用DOAC,且R时间延长、MA增高。
核心结论
- DOAC治疗导致R时间延长,但对血小板抑制无影响。
- 发生MALE的患者更多使用DOAC,R时间延长,且MA增高提示血小板反应性更高,作者认为DOAC可能无法有效预防MALE。
研究设计与样本
- 前瞻性研究,纳入接受下肢血运重建并围术期系列血栓弹力图-血小板映射(TEG-PM)分析的患者。
- 比较使用DOAC与未使用DOAC的患者,并按同期单抗血小板或双抗血小板方案分层。
- 共分析来自141例患者的471份样本。
主要发现
- DOAC联合单抗血小板组较单抗血小板组R时间延长[7.4(±2.4) vs. 6.7(±2.7);P < 0.02],但血小板抑制更少。
- 双抗血小板组血小板抑制程度高于DOAC联合单抗血小板组及单抗血小板组[23.7(±26.9) vs. 31.0(±28.3) vs. 42.2(±31.2);P < 0.01]。
- 发生MALE的患者更多使用DOAC[43.8% vs. 22.0%;P = 0.02]。
- 发生MALE的患者TEG-PM显示R时间延长[8.6(±3.9) vs. 7.3(±3.0);P = 0.05]且MA增高[66.7(±4.2) vs. 61.8(±8.2);P = 0.001]。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of thrombin in vascular pathology is a focus of investigation. The incorporation of direct Factor Xa inhibition into practice patterns is based on its theoretical dual-pathway attenuation of both thrombin generation and platelet aggregation. However, quantification of the effect of direct anti-Xa medications on platelet function is not established. Thromboelastography with platelet mapping (TEG-PM) leverages dual-pathway metrics to provide comprehensive coagulation profiles. We evaluated the effects of direct oral anticoagulants (DOACs) on coagulation and platelet function profiles and correlate these data with postoperative major adverse limb events (MALEs) in patients with PAD. METHODS: We conducted a prospective study of patients undergoing lower extremity revascularization with serial perioperative TEG-PM analysis. Patients on DOACs were compared to those not on DOACs, and stratified by concurrent mono-antiplatelet or dual-antiplatelet regimens (MAPT/DAPT). Postoperative MALE was recorded and difference in antithrombotic regimens and TEG-PM analysis compared between groups. RESULTS: Four hundred seventy-one samples from 141 patients were analyzed. Twenty-nine point five percent were reflective of circulating DOAC therapy. Compared to MAPT alone, patients on DOAC + MAPT exhibited longer time to clot formation (R-time) [7.4 (±2.4) vs. 6.7 (±2.7); P < 0.02], but less platelet inhibition. Patients on DAPT exhibited greater platelet inhibition compared to either group [23.7 (±26.9) vs. 31.0 (±28.3) vs. 42.2 (±31.2); P < 0.01]. Patients who experienced MALE were more likely to be on DOAC therapy [43.8% vs. 22.0% P = 0.02]. Thromboelastography with platelet mapping analysis from patients who experienced MALE also demonstrated longer R-time [8.6 (±3.9 vs. 7.3 (±3.0); P = 0.05] and increased maximum clot amplitude (MA) [66.7 (±4.2) vs. 61.8 (±8.2); P = 0.001]. CONCLUSIONS: Direct oral anticoagulant therapy resulted in a prolonged R-time but had no impact on platelet inhibition. Patients who experienced MALE were more often on DOACs and demonstrated an increased R-time, but also showed greater platelet reactivity evident by increased MA, suggesting DOACs may not be effective at protecting against MALE. Further research comparing DOAC therapy to a DAPT approach may add clarity to emerging multimodal antithrombotic recommendations.
引用
- Hall RP, Majumdar M, Ferreira SS, et al. Impact of Factor Xa Inhibition on Coagulation, Platelet Reactivity, and Thrombosis in Patients with Peripheral Artery Disease. Ann Vasc Surg. 2023. PMID: 37657677. doi:10.1016/j.avsg.2023.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。